Scout vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-native school operating system automating attendance, compliance, and reporting to replace legacy PowerSchool; YC-backed targeting $2B+ K-12 SIS market through PowerSchool dissatisfaction.
About
Scout is an AI-native student information system (SIS) and school operating platform — replacing legacy SIS software like PowerSchool (which the company directly targets) with a modern AI-powered platform that automates the administrative busywork of school operations: attendance tracking, compliance reporting, student data management, government filings, and district-wide workflow automation. Founded and a Y Combinator graduate, Scout positions itself as the antidote to PowerSchool's multi-billion-dollar monopoly that schools pay for through long-term contracts with hidden fees, replacing complex and slow legacy systems with a purpose-built AI-first alternative.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.